ARTICLE | Clinical News
Strimvelis regulatory update
June 6, 2016 7:00 AM UTC
The European Commission approved Strimvelis from GlaxoSmithKline to treat severe combined immunodeficiency (SCID) due to adenosine deaminase deficiency (ADA-SCID) for use in patients for whom a matched bone marrow donor is not available. The ultra-rare disease is caused by inheritance of 2 mutant copies of the gene encoding ADA and results in an inability to make lymphocytes. ...